BET degrader ARV-825 has been used in pre-clinical studies with different cancer types, and we hypothesized that ARV-825 could potentially improve ER+ breast cancer tumor response following Fulvestrant + Palbociclib treatment (59–62). This evidence concerns the gene ESR1 and breast carcinoma.